Current strategies and challenges in vaccine platforms for Newcastle Disease Virus.
6 affiliations
- 1Department of Biology-Geology, Faculty of Science and Technology, Alassane Ouattara University, Bouaké, Côte d'Ivoire. [email protected].
- 2SACIDS Africa Centre of Excellence for Infectious Diseases, SACIDS Foundation for One Health, Sokoine University of Agriculture, Morogoro, 67125, Tanzania. [email protected].
- 3SACIDS Africa Centre of Excellence for Infectious Diseases, SACIDS Foundation for One Health, Sokoine University of Agriculture, Morogoro, 67125, Tanzania.
- 4OR Tambo Africa Research Chair for Viral Epidemics, SACIDS Foundation for One Health, Sokoine University of Agriculture, Morogoro, 67125, Tanzania.
- 5Department of Veterinary Microbiology, Parasitology and Biotechnology, Sokoine University of Agriculture, Morogoro, 67125, Tanzania.
- 6Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, LA1 4YG, UK. [email protected].
Abstract
Newcastle disease virus (NDV) remains one of the most economically devastating pathogens affecting poultry production. Despite decades of vaccination efforts, NDV continues to circulate and remain endemic across Asia, Africa, and the Middle East, posing persistent threats to food security, rural livelihoods, and international trade. This review comprehensively examines the current landscape of NDV vaccine platforms, their immunological mechanisms, and the multifaceted challenges limiting their efficacy. We critically evaluated conventional platforms, including lentogenic live attenuated vaccines and oil-adjuvanted inactivated formulations, highlighting their contributions to disease control while addressing their inherent limitations including cold-chain dependence, maternal antibody interference, incomplete cross-protection against heterologous genotypes, and the absence of differentiating infected from vaccinated animals (DIVA) capability. We then examined next-generation approaches, including recombinant vector platforms, virus-like particles, DNA and mRNA vaccines, and AI/ML-informed antigen design, assessing each against its actual stage of development, from vaccines already in commercial use to platforms that remain preclinical or theoretical, rather than treating design capability as equivalent to field-ready deployment. Finally, we addressed regulatory, manufacturing, and logistical barriers to vaccine deployment in low-resource settings, including a dedicated feasibility assessment and platform-comparison table for smallholder-dominated, endemic regions. Integrating these technological advances with robust surveillance, biosecurity, and supportive policies will be essential for achieving sustainable NDV control and advancing toward eradication.
Related
- Leishmaniasis and vaccine development: current progress, challenges, and future perspectives.
- Immunological Challenges and Emerging Strategies in Dengue Virus Vaccine Development.
- Recombinant Antigen for Newcastle Disease Virus Vaccine Focusing on Currently Circulating Virus Variants.
- Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Genome Editing in Inherited Cardiovascular Diseases: Therapeutic Advances, Emerging Editing Platforms, and Translational Challenges
- Molecular Diagnostics of Pathogenic Vibrio: Target Selection, Detection Platforms, and Challenges in Field Applications.
BibTeX
@article{amoia2026current,
title = {{Current strategies and challenges in vaccine platforms for Newcastle Disease Virus.}},
author = {Charlie Franck Amoia and Gerald Misinzo and Muhammad Munir},
journal = {Tropical diseases, travel medicine and vaccines},
year = {2026},
month = oct,
doi = {10.1186/s40794-026-00320-4},
url = {https://europepmc.org/article/MED/42963803},
note = {CC BY},
}
RIS
TY - JOUR
TI - Current strategies and challenges in vaccine platforms for Newcastle Disease Virus.
AU - Charlie Franck Amoia
AU - Gerald Misinzo
AU - Muhammad Munir
PY - 2026
DA - 2026/10/30
JO - Tropical diseases, travel medicine and vaccines
DO - 10.1186/s40794-026-00320-4
UR - https://europepmc.org/article/MED/42963803
AB - Newcastle disease virus (NDV) remains one of the most economically devastating pathogens affecting poultry production. Despite decades of vaccination efforts, NDV continues to circulate and remain endemic across Asia, Africa, and the Middle East, posing persistent threats to food security, rural livelihoods, and international trade. This review comprehensively examines the current landscape of NDV vaccine platforms, their immunological mechanisms, and the multifaceted challenges limiting their efficacy. We critically evaluated conventional platforms, including lentogenic live attenuated vaccines and oil-adjuvanted inactivated formulations, highlighting their contributions to disease control while addressing their inherent limitations including cold-chain dependence, maternal antibody interference, incomplete cross-protection against heterologous genotypes, and the absence of differentiating infected from vaccinated animals (DIVA) capability. We then examined next-generation approaches, including recombinant vector platforms, virus-like particles, DNA and mRNA vaccines, and AI/ML-informed antigen design, assessing each against its actual stage of development, from vaccines already in commercial use to platforms that remain preclinical or theoretical, rather than treating design capability as equivalent to field-ready deployment. Finally, we addressed regulatory, manufacturing, and logistical barriers to vaccine deployment in low-resource settings, including a dedicated feasibility assessment and platform-comparison table for smallholder-dominated, endemic regions. Integrating these technological advances with robust surveillance, biosecurity, and supportive policies will be essential for achieving sustainable NDV control and advancing toward eradication.
SN - 2055-0936
ER -